How safe is stem cell therapy for women?
Stem cell therapy with mesenchymal stromal cells (MSCs) has a favorable safety profile for women, as it does for men, based on large analyses of randomized trials.
The most consistent side effect of intravenous (IV) MSCs is a temporary fever, without increased rates of infection, blood clots, cancer or death in controlled trials, while local injections commonly cause temporary pain, swelling or bruising. At Stem Cell Mexico, all treatments use allogeneic MSCs derived exclusively from Wharton's jelly (donated umbilical cord tissue), so no harvesting procedure is needed. No medical treatment is risk-free, and safety for women also depends on specific factors: pregnancy and breastfeeding (treatment is not performed), hormonal therapies and contraceptives, autoimmune conditions, bone health, iron levels and a history of breast or gynecological cancer. These are reviewed carefully before any treatment.
This guide explains what the evidence shows, which women's health factors matter and how risks are minimized for each type of treatment.
What the evidence shows
- A systematic review in EClinicalMedicine (Thompson and colleagues, 2020) of 55 randomized trials with 2,696 patients found that intravascular MSCs increased the risk of temporary fever but not of acute infusion toxicity, infections, thrombotic events, malignancy or death.
- A 2026 analysis in Stem Cells Translational Medicine (Hum and colleagues) of 42 randomized trials with 2,280 patients receiving umbilical cord MSCs found the same pattern and recommended ongoing long-term monitoring.
- In a randomized, placebo-controlled trial in older adults with aging frailty, published in The Journals of Gerontology (Tompkins and colleagues, 2017), IV donor MSCs caused no treatment-related serious adverse events.
These studies included women and men; no specific safety signal for women has been identified.
Safety by type of treatment
Joints and spine
Image-guided injections commonly cause pain, swelling and stiffness for several days, or a temporary pain flare after spine procedures. Rare risks include infection, bleeding and nerve irritation.
Hair thinning
Scalp injections, often combining cells with platelet-rich plasma (PRP), can cause tenderness, small pinpoint marks, mild swelling and occasional headache for a few days. Infection is rare.
Skin and aesthetic applications
Applications to the face, neck, décolletage or hands may cause redness, swelling, small bruises or temporary tenderness. Rarely, infection or irregularities can occur. Procedures should be performed with sterile technique by trained professionals.
Systemic wellness (IV infusion)
Mild fever, fatigue or headache for a day or two are the most common effects.
Women's health factors that affect safety
Pregnancy and breastfeeding
Regenerative treatments are not performed during pregnancy or breastfeeding, because safety has not been studied. If there is any chance you could be pregnant, a pregnancy test may be required before treatment. If you are planning a pregnancy soon, discuss timing with the doctor.
Hormonal contraceptives and hormone therapy
Estrogen-containing contraceptives and some forms of hormone replacement therapy (HRT) slightly increase the risk of blood clots, a risk that also rises with long flights and reduced mobility after leg or spine procedures. These medications are usually continued, but the team will review your travel plans and may recommend measures such as hydration, movement and compression stockings. The UK's NICE menopause guideline (NG23) emphasizes individualized discussion of HRT benefits and risks, and any changes should be made with your own doctor.
Autoimmune conditions
Rheumatoid arthritis, lupus, thyroid disease and other autoimmune conditions are more common in women. Some are treated with immunosuppressive medications that affect infection risk and timing. Treatment is postponed during an active flare.
Bone health
Osteoporosis and low vitamin D are common after menopause. They do not prevent treatment, but they matter for spine procedures and fall risk.
Iron deficiency and anemia
Heavy periods can cause iron deficiency, which contributes to fatigue and hair shedding. Pre-treatment blood tests help identify it, and correcting it may improve both safety and results.
Breast and gynecological cancer history
We require at least five years of documented remission for any cancer, including breast, ovarian, uterine and cervical cancers, with oncology follow-up notes. Women taking hormonal cancer-prevention medications, such as tamoxifen or aromatase inhibitors, should share them, as some affect clotting or bone health.
Varicose veins and clotting history
A personal or family history of blood clots is important to disclose, especially if you will travel long distances.
Preparing for treatment
About seven days before treatment, pause anti-inflammatory painkillers, alcohol, tobacco and cannabis; five days before, pause omega 3, turmeric, ginger and similar supplements, and avoid dairy and fried foods. Paracetamol is generally allowed if you need pain relief. Continue your hormonal treatments, thyroid medication and other prescribed drugs unless instructed otherwise, and bring a complete list. If you take blood thinners, never stop them without medical guidance. For scalp or facial treatments, arrive with clean skin and hair and avoid starting new cosmetic products in the days before. Plan comfortable clothing, rest after treatment and, if you are traveling far, a strategy to move and hydrate during the journey.
How we reduce risk
- Medical review of your goals, history, medications and hormonal treatments.
- Pregnancy screening when appropriate.
- Pre-treatment testing: complete blood count, metabolic panel, urinalysis and tumor markers, with additional tests when indicated.
- A single documented cell source: Wharton's jelly MSCs from a COFEPRIS-licensed laboratory under GMP standards, with quality and safety testing before release.
- Image guidance and sterile technique for injections.
- Monitoring and observation after infusions and procedures.
- Travel advice to reduce blood clot risk.
- Clear instructions and follow-up.
After treatment: recovery tips
Rest on the day of treatment and the following day. Avoid alcohol for at least two weeks and continue avoiding anti-inflammatory painkillers and supplements as instructed. After scalp or facial treatments, follow the specific guidance on washing, makeup and sun exposure. After joint or spine procedures, return to exercise gradually from the second week. Keep follow-up calls and report unexpected symptoms early.
Why we use only Wharton's jelly MSCs
All our treatments use the same well-characterized source: MSCs from umbilical cords donated after healthy, full-term births. You avoid liposuction or bone marrow aspiration and their harvest-site risks, the cells' quality does not depend on your age or health, and each batch is tested and documented. MSCs provoke very little immune response, so matching is not required. Rare allergic reactions are still possible with any biological product, which is why screening and observation are part of every protocol.
Women over 60 and safety
Many women seeking regenerative treatment are postmenopausal and living with osteoarthritis, back pain or fatigue. In this group, safety planning gives particular attention to bone density, fall risk, blood pressure, kidney function and the combined effect of several medications. Fasting and sedation can cause dizziness, so standing up slowly, staying hydrated as allowed and having assistance when walking in unfamiliar places help prevent falls. Age itself does not exclude treatment, and older adults have been included in many MSC studies without specific safety concerns.
Safety is not the same as effectiveness
Evidence of benefit is strongest for joint and spine conditions. There is no evidence that stem cell therapy treats menopausal symptoms, and it is not an established treatment for fertility or ovarian function. The International Society for Stem Cell Research (ISSCR) recommends asking for the evidence behind any treatment for your specific goal.
Regulatory context
The FDA has not approved umbilical cord MSC or exosome products for these uses. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.
Who may be a safe candidate
- A clear goal with a diagnosis that regenerative treatment may reasonably support.
- Not pregnant or breastfeeding.
- Hormonal therapies reviewed, and clot risk assessed for travel.
- No active infection, active autoimmune flare or cancer within the past five years.
- Realistic expectations and willingness to follow preparation and recovery instructions.
Signs to report after treatment
Seek urgent care for calf pain or swelling, chest pain or sudden shortness of breath (possible blood clot), high or persistent fever, increasing redness or swelling at an injection site, new weakness or numbness, or signs of an allergic reaction.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- For a joint or the spine: 20 to 40 million Wharton's jelly MSCs per treated area, applied by direct injection with ultrasound or fluoroscopy guidance, often together with platelet-rich plasma (PRP).
- For systemic goals: Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on body weight and medical review.
- One night at our facilities with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- What are the specific risks of my procedure?
- How do my contraceptive or hormone therapy affect safety and travel?
- Do I need a pregnancy test or other tests first?
- How does my autoimmune condition or cancer history affect eligibility?
- What monitoring and follow-up will I have?
Bottom line
For women, stem cell therapy has a favorable general safety profile, with mostly temporary side effects that depend on the procedure. Safety is strengthened by excluding pregnancy and breastfeeding, reviewing hormonal treatments and clot risk, addressing autoimmune, bone and iron health, and using a documented Wharton's jelly cell product with monitoring. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your goals, health and medical history.
References
- Thompson M et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine, 2020 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
- NICE guideline NG23: Menopause, identification and management (opens in a new tab)
- Tompkins BA et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial. The Journals of Gerontology, Series A, 2017 (opens in a new tab)
- International Society for Stem Cell Research (ISSCR): The ISSCR Guide to Stem Cell Treatments (opens in a new tab)
